ConductScience.org, home
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
API referenceFor AI assistants

Trial · NCT00835770

Results by group512

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 512

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Treatment-Emergent Adverse Events (AEs)BG00012 240 mg BID824Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)BG00012 240 mg TID814Participants
Percentage of Participants Who Had RelapsesBG00012 240 mg BID (Prior BG00012 240 mg BID)40percentage of participants
Percentage of Participants Who Had RelapsesBG00012 240 mg TID (Prior BG00012 240 mg TID)41percentage of participants
Percentage of Participants Who Had RelapsesBG00012 240 mg BID (Prior BG00012 Matched Placebo)34percentage of participants
Percentage of Participants Who Had RelapsesBG00012 240 mg TID (Prior BG00012 Matched Placebo)36percentage of participants
Percentage of Participants Who Had RelapsesBG00012 240 mg BID (Prior Glatiramer Acetate [GA])31percentage of participants
Percentage of Participants Who Had RelapsesBG00012 240 mg TID (Prior Glatiramer Acetate [GA])31percentage of participants
Annualized Relapse Rate (ARR)BG00012 240 mg BID (Prior BG00012 240 mg BID)0.159relapses per participant-years
Annualized Relapse Rate (ARR)BG00012 240 mg TID (Prior BG00012 240 mg TID)0.179relapses per participant-years
Annualized Relapse Rate (ARR)BG00012 240 mg BID (Prior BG00012 Matched Placebo)0.200relapses per participant-years
Annualized Relapse Rate (ARR)BG00012 240 mg TID (Prior BG00012 Matched Placebo)0.199relapses per participant-years
Annualized Relapse Rate (ARR)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])0.184relapses per participant-years
Annualized Relapse Rate (ARR)BG00012 240 mg TID (Prior Glatiramer Acetate [GA])0.212relapses per participant-years
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384BG00012 240 mg BID (Prior BG00012 240 mg BID)Baseline2.44Standard Deviation 1.251score on a scale
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384BG00012 240 mg TID (Prior BG00012 240 mg TID)Baseline2.43Standard Deviation 1.144score on a scale
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384BG00012 240 mg BID (Prior BG00012 Matched Placebo)Baseline2.50Standard Deviation 1.135score on a scale
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384BG00012 240 mg TID (Prior BG00012 Matched Placebo)Baseline2.54Standard Deviation 1.218score on a scale
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384BG00012 240 mg BID (Prior Glatiramer Acetate [GA])Baseline2.57Standard Deviation 1.249score on a scale
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384BG00012 240 mg TID (Prior Glatiramer Acetate [GA])Baseline2.68Standard Deviation 1.231score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00835770/results

API referenceFor AI assistants